CTRI/2021/04/033010招募中2 期
Clinical Evaluation of Efficacy and Safety of Dabur Ayurvedic Oils in Comparison to a Marketed Comparator and â??No Treatmentâ?? arm for hair growth and hair fall reduction in healthy adult volunteers
试验速览
- 阶段
- 2 期
- 状态
- 招募中
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1)Subjects in general good health.
- •2)Subjects in the age group 18-45 years (both the ages inclusive).
- •3)Subjects complaining of hair fall and damage.
- •4)Subjects willing to give a written informed consent and willing to abide by and comply with the study protocol.
- •5)Hair density of >100 and <200 hair follicle per square cm as per Trichoscan measurement
- •6)Male and Female Subjects falling under Grade 3 - Grade 6 of hair loss severity grade evaluated as per MSCR photo numerical 10-point scale (Linear scale for assessment purpose-In Use Scale).
- •7)Subjects with mild or moderate dandruff condition based on the total adherent and non adherent score.
- •8)The subjects who agree to refrain from using hair dye / hair colour during the study period.
排除标准
- •1)Subjects who have undergone hair growth treatment within 3 months before screening into the study.
- •2)Subjects having any active scalp disease which may interfere in the study â?? dermatologistâ??s judgement.
- •3)Subjects who have taken chemotherapy for cancer in the 6 months prior to start of the study or have a plan to do treatments during study.
- •4)Subjects who have history of alcoholism, smoking, crash dieting and/ or psychiatric disorder including trichotillomania.
- •5)Subjects who have had hair transplant, who have taken pharmaceutical product which cause hirsutism (ex. phenytoin) and finasteride for androgenic alopecia, under medical treatment for hair problems.
- •6)A known history or present condition of allergic response/hypersensitivity to any cosmetic ingredients and pharmaceutical products.
- •7)Subjects on oral medications, undergoing any chemical hair salon treatment-straightening / perming / colour/ henna which will compromise the study.
- •8)Subjects with chronic illness which may influence the cutaneous state.
- •9)Subjects who are pregnant or lactating or nursing as established with medical history
- •10)Menopausal female subjects as determined by medical history.
- •11)Subjects participating in other similar cosmetic or therapeutic trial within last three months.
- •12)Subjects with any history of underlying uncontrolled medical illness including diabetes mellitus, hypertension, HIV, hepatitis, severe anemia, serious disorder of heart and respiratory apparatus or any other serious medical illness.
- •1)Subjects who have undergone hair growth treatment within 3 months before screening into the study.
- •2)Subjects having any active scalp disease which may interfere in the study â?? dermatologistâ??s judgement.
- •3)Subjects who have taken chemotherapy for cancer in the 6 months prior to start of the study or have a plan to do treatments during study.
- •4)Subjects who have history of alcoholism, smoking, crash dieting and/ or psychiatric disorder including trichotillomania.
- •5)Subjects who have had hair transplant, who have taken pharmaceutical product which cause hirsutism (ex. phenytoin) and finasteride for androgenic alopecia, under medical treatment for hair problems.
- •6)A known history or present condition of allergic response/hypersensitivity to any cosmetic ingredients and pharmaceutical products.
- •7)Subjects on oral medications, undergoing any chemical hair salon treatment-straightening / perming / colour/ henna which will compromise the study.
- •8)Subjects with chronic illness which may influence the cutaneous state.
- •9)Subjects who are pregnant or lactating or nursing as established with medical history
- •10)Menopausal female subjects as determined by medical history.
- •11)Subjects participating in other similar cosmetic or therapeutic trial within last three months.
- •12)Subjects with any history of underlying uncontrolled medical illness including diabetes mellitus, hypertension, HIV, hepatitis, severe anemia, serious disorder of heart and respiratory apparatus or any other serious medical illness.
研究者
相似试验
已完成
不适用
Clinical Study of Dabur VatikaNilibringhadi Gold Hair GrowthOil in Comparison to a MarketedComparator and â??No Treatmentâ??arm in healthy Human VolunteersCTRI/2020/02/023127Dabur India Limited111
已完成
不适用
The clinical study of the safety and efficacy of docetaxel combined with ribavirin in docetaxel resistant castration resistant prostate cancerProstate cancerJPRN-UMIN000015130Keio University School of Medicine, Department of Urology20
招募中
不适用
Evaluation of efficacy and safety of Dabigaran in patients with catheter ablation for atrial fibrillation.Atrial fibrillationJPRN-UMIN000011223Osaka City University Graduate School of Medicine140
尚未招募
2 期
Efficacy of Unani Formulation in White PatchesCTRI/2022/04/041571Rajiv Gandhi University Of Health Sciences
进行中（未招募）
2 期
PMX-DHP for COVID-19JPRN-jRCTs032200131Izumi Shinnyuu30